PIONEER is a randomised Phase II trial in early stage, operable ER+ breast cancer. This is a ‘window of opportunity’ trial in which three groups of post-menopausal women will receive two weeks of drug treatment prior to surgery.
Artesunate (ART) is a water soluble semisynthetic artemisinin with improved pharmacokinetic properties, and is included in the WHO list as an essential drug for the treatment of malaria. The antitumor and antiangiogenic effects of ART were investigated in a carcinogenic-induced mouse model for Hepatocellular carcinoma.
This randomized study, where patients are randomly divided over the treatment group and control group, will compare the standard treatment with nivolumab to the experimental treatment with a combination of 3 oral drugs that are currently on the market for other indications than lung cancer.
The activation and expansion of tumor reactive T cells outside the body of patients and their subsequent re-infusion of adoptive cell transfer (ACT) is at this moment the most effective approach to induce objective anti-tumor responses in end-stage metastasized melanoma cancer patients.
A pilot clinical trial to evaluate the biologic effects, safety and efficacy of palliative treatment with ultra-low dose paclitaxel (Taxol®) in patients with metastatic melanoma in stage IV or III unresectable.
In the USA, impressive results have been obtained in melanoma patients treated with lymphodepleting chemotherapy, followed by ACT with high numbers of ex vivo expanded autologous TIL and IL-2 (cytokine stimulating T cell expansion). The first comparable clinical trial in Europe has not yet been completed, but the results are comparable and promising.
The current project aims to expand this treatment to ovarian cancer patients.
If you would like to submit a project to the Anticancer Fund that is in line with our vision and mission please send a summary of approx. 500 words to info@anticancerfund [dot] org. Anticancer Fund is especially interested in research on cancer treatments that put into practice new ideas and methods that could result in a leap frog forward in survival of cancer patients.
More precisely, the Anticancer Fund wants to support these developments that fall outside the focus of the pharmaceutical industry and the institutional research. The Anticancer Fund will continuously select projects for in depth evaluation. In case your project is choosen, a detailed research plan, milestones, timeline and budget will be required for further assessment by a panel of experts.
A compilation of questions the Anticancer Fund has received from patients or their relatives. All of these answers have been carefully written by professionals of our team for informational purpose only. Go to the Questions